Nanomedicine first-in-human research: challenges for informed consent

Area of Science:

• Nanomedicine
• Biotechnology
• Medical Ethics

Background:

• First-in-human research presents inherent risks, including harm, translational uncertainty, and unclear direct benefits.
• Nanomedical technologies introduce unique considerations such as defining interventions and understanding bystander risks.
• The common use of nanomaterials outside medicine and unknowns about nanosize effects complicate informed consent.

Purpose of the Study:

• To identify and discuss the specific challenges in obtaining informed consent for first-in-human nanomedicine research.
• To outline key areas that require careful consideration when consenting participants to nanomedicine trials.
• To propose strategies for addressing the complexities of nanomedicine in the informed consent process.

Main Methods:

• Literature review and ethical analysis of existing frameworks for human research.
• Identification of unique characteristics of nanomedical technologies relevant to informed consent.
• Discussion of potential risks, uncertainties, and ethical considerations specific to nanomedicine.

Main Results:

• Key issues include defining nanomedical interventions, bystander risks, and the therapeutic misconception.
• The context of widespread nanomaterial use and persistent unknowns about nanosize effects must be addressed.
• Standard informed consent procedures may be insufficient for nanomedicine research.

Conclusions:

• Informed consent for first-in-human nanomedicine research requires a tailored approach.
• Addressing definitional ambiguities, bystander risks, and the therapeutic misconception is crucial.
• Enhanced communication and transparency are necessary to ensure truly informed consent in this field.